10-Q: MeiraGTx Q3 2025: Strategic Deals Bolster Cash, Losses Persist

MeiraGTx reports continued net losses in Q3 2025 but strengthens its financial position with significant upfront payments from new strategic collaborations with Eli Lilly and Hologen.

Summary

• Net loss for the three months ended September 30, 2025, was $(50.5) million, compared to $(39.3) million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(129.3) million, compared to $(108.4) million for the same period in 2024.
• The accumulated deficit as of September 30, 2025, totaled $831.3 million.
• Cash, cash equivalents, and restricted cash decreased to $17.1 million as of September 30, 2025, from $105.7 million at December 31, 2024.
• A strategic collaboration with Hologen Limited, signed March 9, 2025, includes an expected $200 million upfront cash payment, with $50 million received to date ($28 million in Q3 2025 and $22 million in Q4 2025). Hologen also committed up to an additional $230 million to fund the Hologen Neuro AI Ltd joint venture.
• A strategic collaboration with Eli Lilly and Company, effective November 7, 2025 (post-period), includes a $75 million upfront payment and eligibility for over $400 million in total milestone payments, including up to $135 million in potential near-term cash consideration.
• The company estimates that its cash on hand, receivables, and anticipated collaboration payments will be sufficient to fund operating expenses and capital expenditures into the second half of 2027 and repay its $75 million debt obligation to Perceptive due August 2026.
• Research and development expenses increased to $32.5 million for Q3 2025 from $26.2 million in Q3 2024, and to $98.8 million for the nine months ended September 30, 2025, from $95.5 million in 2024.
• Service revenue from related parties decreased to $0.4 million for Q3 2025 from $10.9 million in Q3 2024, and to $6.0 million for the nine months ended September 30, 2025, from $11.9 million in 2024, primarily due to the substantial completion of PPQ services under the Asset Purchase Agreement.
• AAV-hAQP1 for radiation-induced xerostomia received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in December 2024, with Phase 2 AQUAx2 enrollment targeted for completion by year-end 2025 and potential BLA filing in early 2027.
• AAV-GAD for Parkinson's disease received RMAT designation from the FDA in May 2025, with a Phase 3 study aiming to initiate in the coming months.
• The company acquired certain assets and operations of Smart Immune, including its ProTcell platform and 20 employees, in July 2025 for €250,000 plus a €100,000 transfer fee.

Sentiment

Score: 6

Explanation: While the company reported increased net losses and a significant decrease in cash for the period, the announcement of substantial upfront payments from new strategic collaborations with Eli Lilly ($75M) and Hologen ($200M total, $50M received to date) significantly bolsters its liquidity and extends its cash runway into H2 2027. Progress in clinical programs (RMAT designations for AAV-hAQP1 and AAV-GAD, positive Phase 3 data for bota-vec) and the acquisition of Smart Immune assets also provide positive momentum, despite the ongoing operational losses typical for a clinical-stage biotech.

Positives

• Secured significant upfront payments from new strategic collaborations: $75 million from Eli Lilly (post-period) and $50 million received to date from Hologen ($28 million in Q3 2025, $22 million in Q4 2025).
• Hologen committed up to an additional $230 million to fund the Hologen Neuro AI Ltd joint venture for the development of AAV-GAD and other CNS genetic medicines.
• Extended cash runway: Estimated funds (including collaboration payments) are sufficient to fund operating expenses and capital expenditures into the second half of 2027 and repay the $75 million debt due August 2026.
• AAV-hAQP1 for radiation-induced xerostomia received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in December 2024, aligning with the agency on clinical and CMC requirements for a potential BLA.
• AAV-GAD for Parkinson's disease received RMAT designation from the FDA in May 2025, based on positive data from three clinical studies.
• Positive Phase 3 LUMEOS data for botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa was presented in May 2025, receiving strong support from the Foundation Fighting Blindness for filing and approval.
• Acquired Smart Immune assets, including the ProTcell T-cell progenitor-based cell therapy platform and 20 employees, for €350,000, expanding cell therapy capabilities.
• Maintained internal end-to-end manufacturing capabilities, including two GMP viral vector production facilities and internal plasmid production, supporting IND through commercial supply.
• Proprietary manufacturing platform demonstrates leading yield and quality aspects with commercial readiness.
• Riboswitch gene regulation platform is progressing its first program (native human leptin for metabolic disease) into the clinic, showing durable leptin production and efficacy in mouse models past one year.

Negatives

• Net loss for the three months ended September 30, 2025, increased to $(50.5) million from $(39.3) million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $(129.3) million from $(108.4) million in the prior year period.
• Cash, cash equivalents, and restricted cash significantly decreased from $105.7 million at December 31, 2024, to $17.1 million at September 30, 2025.
• The accumulated deficit grew to $831.3 million as of September 30, 2025.
• Service revenue (related party) decreased significantly to $0.4 million for the three months ended September 30, 2025, from $10.9 million in the prior year period, primarily due to the substantial completion of PPQ services.
• Cost of service revenue (related party) decreased to $0.3 million for the three months ended September 30, 2025, from $12.0 million in the prior year period, reflecting the completion of PPQ services.
• Experienced a foreign currency loss of $1.6 million in Q3 2025, compared to a gain of $3.5 million in Q3 2024, primarily due to the weakening of the U.S. dollar against the pound sterling and euro.
• Interest income decreased by $1.0 million in Q3 2025 due to lower interest rates and cash balances held in interest-bearing accounts.
• No gain on sale of nonfinancial assets was recognized during the nine months ended September 30, 2025, compared to $28.4 million in the prior year, as the related milestone was fully recognized in previous periods.

Risks

• Incurred significant losses since inception and anticipate continued losses for the foreseeable future, and may never achieve or maintain profitability.
• There is no guarantee of timely receipt or receipt at all of additional milestone payments contemplated under the Asset Purchase Agreement or revenues associated with the manufacture of the commercial supply of the RPGR Product under the Supply Agreement.
• Will require additional capital to fund operations, which may not be available on acceptable terms, if at all.
• May not have sufficient cash flows or cash on hand to satisfy debt obligations or covenants under financing arrangements, or may not be able to effectively manage the business in compliance with such covenants.
• Review of potential strategic transactions may not result in an executed or consummated transaction or other strategic alternative and may not result in anticipated benefits, and the process could be disruptive.
• Heavily dependent on the success of product candidates, which are still in development; business may be harmed if none receive regulatory approval or are successfully commercialized.
• It is difficult to predict the time and cost of product candidate development on the novel gene therapy platform, as a limited number of gene therapies have been approved.
• The regulatory landscape governing gene therapy product candidates is uncertain and may change, making it difficult to predict the time and cost of obtaining regulatory approval.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome; substantial delays may be encountered.
• The affected populations for product candidates may be smaller than projected, which may affect the addressable markets.
• Subject to significant regulation with respect to manufacturing products; manufacturing facilities and third-party facilities may not continue to meet regulatory requirements and have limited capacity.
• Enacted and future healthcare legislation may increase the difficulty and cost to obtain marketing approval and commercialize product candidates, and may affect prices.
• Subject to regulation and other legal obligations relating to data privacy and protection; non-compliance could materially harm the business.
• Faces significant competition in an environment of rapid technological change; competitors may achieve regulatory approval before or develop safer/more effective therapies.
• Depends on proprietary technology licensed from others; loss of existing licenses or inability to acquire additional proprietary rights could prevent continued product candidate development.
• If unable to obtain and maintain patent protection for technology and product candidates, or if the scope is not sufficiently broad, may not be able to compete effectively.
• May need to increase or decrease the size of the organization and may experience difficulties in managing these organizational changes, which could disrupt operations.
• Future success depends on the ability to retain key personnel and to attract, retain, and motivate qualified personnel.
• Pandemics, epidemics, or outbreaks of an infectious disease have impacted and may in the future materially and adversely impact the business, including preclinical studies, clinical trials, manufacturing capabilities, and regulatory approvals.
• Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact public perception of current and future product candidates.
• May fail to maintain the benefits of certain regulatory designations (e.g., RMAT, orphan drug) or fail to obtain such designations for other candidates, and such designations do not guarantee faster development or approval.
• No guarantee that FDA approval of any rare pediatric disease gene therapy candidates will result in a priority review voucher.
• Interim, topline, and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• May expend limited resources to pursue a particular product candidate or indication and fail to capitalize on more profitable or successful opportunities.
• Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other government or regulatory agencies could hinder timely development, approval, or commercialization.
• Potential product liability lawsuits could cause substantial liabilities and limit commercialization.
• Insurance policies are expensive and protect only from some business risks, leaving exposure to significant uninsured liabilities.
• Employees and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards, which could harm the business.
• Business and operations may suffer in the event of system failures, and systems may be vulnerable to cybersecurity risks.
• The use or anticipated use of new and evolving technologies, such as artificial intelligence (AI), by the company or third parties may increase or create new operational risks.
• The market price of ordinary shares may be volatile and fluctuate substantially, which could result in substantial losses for purchasers.
• May raise additional capital pursuant to its shelf registration statement, including through its at-the-market offering program, or through additional public or private placements, any of which could substantially dilute the investment of stockholders.
• Executive officers, directors, and principal shareholders, if they choose to act together, have the ability to significantly influence all matters submitted to shareholders for approval.
• As a smaller reporting company, the reduced disclosure requirements may make ordinary shares less attractive to investors.
• Anti-takeover provisions in organizational documents and Cayman Islands law may discourage or prevent a change of control.
• There may be difficulties in enforcing foreign judgments against management or the company.
• The rights of shareholders differ from the rights typically offered to shareholders of a U.S. corporation.
• May be classified as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. investors.
• If a United States person is treated as owning at least 10% of ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences.
• Changes in tax laws or challenges to the tax position could adversely affect results of operations and financial condition.
• May engage in acquisitions that could disrupt the business, cause dilution to shareholders, or reduce financial resources.
• Exchange rate fluctuations may adversely affect results of operations and financial condition.
• Management team has broad discretion as to the use of net proceeds from public and private equity or debt financings, and the investment of these proceeds may not yield a favorable return.
• Incurs substantial costs as a public company, and management is required to devote substantial time to new and existing compliance initiatives and corporate governance practices.
• If securities or industry analysts cease to publish research or reports about the business, or if they issue an adverse or misleading opinion, share price and trading volume could decline.
• Expectations relating to environmental, social, and governance factors may impose additional costs and expose the company to new risks.
• Does not anticipate paying any cash dividends on ordinary shares in the foreseeable future; capital appreciation, if any, would be the sole source of gain.

Future Outlook

MeiraGTx expects to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through preclinical and clinical development, expands research, development, and manufacturing activities, and develops new product candidates. Research and development and general and administrative costs are anticipated to increase. The strategic collaboration with Hologen is expected to close in Q4 2025, providing substantial funding. The AAV-hAQP1 Phase 2 AQUAx2 study is targeting enrollment completion by the end of 2025, with potential pivotal data readout in early 2027 for a BLA filing and potential approval later in 2027. The Phase 3 study for AAV-GAD is expected to initiate in the coming months. A new program for severe chronic neuropathic pain is projected to enter the clinic in the first half of 2026, and the riboswitch program for metabolic disease is also progressing to the clinic.

Management Comments

• Our cash and cash equivalents on-hand, tax incentive receivable and accounts receivable – related party at September 30, 2025, together with the $75.0 million upfront payment from Eli Lilly and Company, and the $22.0 million deposit received from Hologen to date during the fourth quarter 2025 and the remaining $150.0 million from the anticipated closing of the strategic collaboration with Hologen, will be sufficient to cover its expenses for at least the next twelve months from the date of issuance of these condensed consolidated financial statements.
• This estimate does not include the $135.0 million in potential near-term cash consideration from Lilly upon the achievement of certain development and regulatory approval milestones.
• This estimate also does not include the $285.0 million in milestones we are eligible to receive under the Asset Purchase Agreement upon first commercial sale of an RPGR Product in the United States and in at least one of the United Kingdom, France, Germany, Spain and Italy, for completion of the transfer of certain manufacturing technology to Johnson & Johnson Innovative Medicine and upon regulatory approval of a Johnson & Johnson Innovative Medicine-selected manufacturing facility in each of the United States and European Union, or EU, for commercial manufacture of the RPGR Product.
• We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect.
• We expect to continue incurring costs associated with our clinical activities for AAV-hAQP1 for the treatment of radiation-induced xerostomia and xerostomia associated with Sjogrens syndrome, AAV-GAD for the treatment of Parkinson's disease, as well as costs associated with the delivery of services under the Asset Purchase Agreement and related agreements.
• We also incurred expenses during the nine-month period ended September 30, 2025 and expect to continue to incur expenses related to research activities in additional therapeutic areas to expand our pipeline, developing our potentially transformative gene regulation technology, hiring additional personnel as needed in manufacturing, research, clinical operations, quality and other functional areas, and associated cash and share-based compensation expense, as well as the further development of internal manufacturing capabilities and capacity and other associated costs including the management of our intellectual property portfolio.
• We will require additional capital in the future, which we may raise through equity offerings (including our at-the-market equity offering program), debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable us to complete the development and potential commercialization of our product candidates.
• Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy.
• If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our research and development programs.

Industry Context

MeiraGTx operates in the highly competitive and rapidly evolving gene therapy and genetic medicines industry. The company's strategic collaborations with Eli Lilly and Hologen reflect a common industry trend where clinical-stage biotechs partner with larger pharmaceutical companies to secure funding, de-risk development, and leverage commercialization capabilities. The emphasis on internal end-to-end manufacturing capabilities positions MeiraGTx to potentially mitigate supply chain risks and control costs, a key differentiator in an industry often reliant on external contract manufacturing. The acquisition of Smart Immune assets expands its reach into cell therapy, aligning with broader industry innovation in advanced therapeutics. The RMAT designations for AAV-hAQP1 and AAV-GAD highlight the company's focus on addressing serious unmet medical needs, a strategy often supported by regulatory incentives.

Comparison to Industry Standards

• Gene Therapy Approvals: The company operates in a novel field with a limited number of gene therapies approved in the U.S. or Europe, indicating a high-risk, high-reward environment with evolving regulatory pathways.
• Competition: MeiraGTx faces significant competition from major pharmaceutical and biotechnology companies with greater financial resources and expertise, including Spark Therapeutics, Inc. (Luxturna for RPE65-associated retinal disease), Applied Genetic Technologies Corporation, 4D Molecular Therapeutics, Inc., Voyager Therapeutics, Inc., Brain Neurotherapy Bio, Inc., and Eli Lilly and Company (also a collaborator).
• Manufacturing Capabilities: The company's internal end-to-end GMP viral vector and plasmid production facilities provide a competitive advantage by reducing reliance on external contract manufacturing organizations (CMOs), which can be a bottleneck in the gene therapy industry.
• Strategic Collaborations: The collaborations with Johnson & Johnson Innovative Medicine, Hologen, and Eli Lilly are consistent with industry practices for clinical-stage biotechs seeking to fund development, share risks, and access commercialization infrastructure, with upfront payments and milestone structures being standard.
• Regulatory Designations: Receiving Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-hAQP1 and AAV-GAD, and multiple Orphan Drug designations, aligns with industry strategies to leverage expedited regulatory pathways and incentives for promising therapies targeting serious or rare conditions.
• Riboswitch Technology: The development of a proprietary riboswitch gene regulation platform represents an innovative approach within gene therapy, potentially offering a differentiated mechanism for precise, dose-responsive control of transgene expression compared to traditional methods.

Corporate Governance

Legal Proceedings

• We are not subject to any material legal proceedings.

Related Party Transactions

• Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals, Inc.): Under the Asset Purchase Agreement (December 20, 2023), the company sold the UCLB RPGR License Agreement and related assets. Received a $65.0 million upfront payment in December 2023 and $60.0 million in milestone payments during 2024. Eligible for up to $350.0 million in future contingent consideration. The company also entered into a Supply Agreement to manufacture and supply the RPGR Product for an initial term of four years. Service revenue from related party for PPQ services was $0.4 million for Q3 2025 and $6.0 million for 9M 2025.
• Hologen Limited: Entered into a strategic collaboration (Framework Agreements) on March 9, 2025, which includes an expected $200 million upfront cash payment on the Closing Date (expected Q4 2025). $28.0 million was received in Q3 2025, and an additional $22.0 million in Q4 2025. The company received 250,000 Class A shares of Hologen at a nominal price, with an option for an additional 500,000 shares if funding obligations are not met. Hologen committed up to an additional $230 million to fund the Hologen Neuro AI Ltd joint venture, in which MeiraGTx Neuro UK will hold a 30% ownership.
• Perceptive Credit Holdings III, LP: The company has a senior secured financing arrangement (Notes Purchase Agreement, converted December 19, 2022) with Perceptive, providing an initial $75.0 million notes issuance (Tranche 1 Notes) maturing August 2, 2026. Perceptive Advisors, LLC, an affiliate of Perceptive, is a greater than 10% holder of the company's ordinary shares. Ellen Hukkelhoven, Ph.D., a director of the company, is an employee of Perceptive Advisors, LLC. The company granted warrants to Perceptive to purchase 700,000 ordinary shares at exercise prices of $15.00 and $20.00 per share, expiring August 2, 2027.

Stakeholder Impact

• Shareholders: Face potential dilution from future equity offerings and continued stock price volatility. The strategic collaborations provide significant capital, potentially enhancing long-term value, but operational losses persist. Executive officers, directors, and principal shareholders maintain significant influence.
• Employees: The acquisition of Smart Immune assets included 20 employees, expanding the workforce. Future growth and strategic shifts may impact staffing levels and require additional hiring and integration.
• Customers/Collaborators (Johnson & Johnson Innovative Medicine, Eli Lilly, Hologen): Johnson & Johnson Innovative Medicine continues to receive manufacturing and supply services for the RPGR Product. Eli Lilly will research, develop, and commercialize AAV-AIPL1 and other ophthalmology candidates. Hologen will collaborate on neurodegenerative programs and manufacturing, leveraging AI capabilities.
• Creditors (Perceptive Credit Holdings III, LP): The company has a $75.0 million debt obligation due August 2026, which it estimates it has sufficient funds to repay. Compliance with debt covenants is ongoing.
• Patients: The advancement of clinical programs for Parkinson's disease (AAV-GAD), radiation-induced xerostomia (AAV-hAQP1), AIPL1-associated retinal dystrophy (AAV-AIPL1), and a new program for severe chronic neuropathic pain offers potential new genetic medicine treatments for severe unmet needs.

Next Steps

• Closing of the strategic collaboration with Hologen Limited is expected in the fourth calendar quarter of 2025.
• Enrollment for the Phase 2 AQUAx2 study for AAV-hAQP1 is targeted for completion by the end of 2025.
• Initiation of the Phase 3 study for AAV-GAD is planned for the coming months.
• Potential pivotal data readout for the AAV-hAQP1 Phase 2 AQUAx2 study is anticipated in early 2027, supporting a potential BLA filing.
• Potential approval for AAV-hAQP1 is projected for later in 2027.
• A new program for severe chronic neuropathic pain is expected to enter the clinic in the first half of 2026.
• The riboswitch program for metabolic disease (native human leptin) is progressing towards clinical entry.
• Negotiate and enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd for AAV-GAD and other locally-delivered genetic medicines targeting the CNS.
• Hologen has an exclusive, irrevocable option to purchase additional shares in MeiraGTx Manufacturing for twelve months following the Hologen Closing Date, to achieve 40% ownership.
• MeiraGTx has an exclusive, irrevocable option to purchase all shares of MeiraGTx Manufacturing held by Hologen, exercisable from the third anniversary of the Hologen Closing Date for three years.

Key Dates

Recommendation

While MeiraGTx reported increased net losses and a significant cash burn for the quarter, the recent strategic collaborations with Eli Lilly and Hologen are transformative. The combined upfront payments of $125 million (Lilly $75M, Hologen $50M received to date) and additional committed funding from Hologen ($230M) substantially de-risk the company's financial position, extending its cash runway into H2 2027 and covering its debt repayment. This provides crucial capital for advancing its late-stage clinical pipeline, including RMAT-designated programs for Parkinson's disease (AAV-GAD) and radiation-induced xerostomia (AAV-hAQP1). The acquisition of Smart Immune assets also diversifies its therapeutic platforms. However, the company remains clinical-stage with no product revenue, faces high R&D costs, and is subject to significant regulatory and competitive risks inherent in gene therapy development. The long path to profitability and potential for further dilution from future capital raises warrant a cautious stance. The strategic partnerships provide a strong foundation, but execution risk remains high.

Keywords

Gene therapy, Genetic medicines, Parkinson's disease, Radiation-induced xerostomia, AIPL1-associated retinal dystrophy, Riboswitch technology, AAV-GAD, AAV-hAQP1, AAV-AIPL1, Biotechnology, Clinical-stage, Manufacturing, Orphan drug, RMAT designation, Eli Lilly, Hologen, Strategic collaboration, SEC filing, 10-Q